Literature DB >> 28735644

Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype?

Benito Chiofalo1, Antonio Simone Laganà2, Vittorio Palmara2, Roberta Granese2, Giacomo Corrado3, Emanuela Mancini3, Salvatore Giovanni Vitale2, Helena Ban Frangež4, Eda Vrtačnik-Bokal4, Onofrio Triolo2.   

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine system disorder among women of reproductive age. In several cases, PCOS women show infertility or subfertility and other metabolic alteration, such as insulin resistance (InsR), dyslipidaemia, hyperinsulinemia and obesity. Despite the aetiology of the syndrome is still far from be elucidated, it could be considered the result of concurrent endocrine modifications, lifestyle factors and genetic background. In particular, accumulating evidence suggests that InsR and compensatory hyperinsulinemia play a pivotal pathogenic role in the hyperandrogenism of many PCOS phenotypes, which in turn have a clear detrimental effect on chronic anovulation. Different forms of fasting, such as intermittent fasting (IF, including alternate day fasting, or twice weekly fasting, for example) and periodic fasting (PF, lasting several days or longer every 2 or more weeks) are currently being tested in several in vitro and in vivo studies. Changes in the circulating levels of Insulin Growth Factor-1 (IGF-1), Insulin-like Growth Factor-Binding Protein 1 (IGFBP1), glucose and insulin are typical effects of fasting which may play a key role on aging and metabolic homeostasis. Considering the paramount importance of InsR and compensatory hyperinsulinemia, different fasting regimens can reduce IGF-1, IGFBP1, glucose and insulin levels and consequently have beneficial effects on ovarian function, androgen excess and infertility in PCOS women.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diet; Fasting; Insulin resistance; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2017        PMID: 28735644     DOI: 10.1016/j.mehy.2017.06.013

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  17 in total

1.  Influence of Insulin on LH, Testosterone and SHBG in various PCOS Categories based on the Mode of Secretion of LH in relation to FSH Levels.

Authors:  N A Malini; G K Roy
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

2.  Endometriosis Increases the Risk of Placenta Previa in Both IVF Pregnancies and the General Obstetric Population.

Authors:  Eider Gómez-Pereira; Jorge Burgos; Rosario Mendoza; Irantzu Pérez-Ruiz; Fátima Olaso; David García; Iker Malaina; Roberto Matorras
Journal:  Reprod Sci       Date:  2022-08-23       Impact factor: 2.924

3.  ANTI-THYROID ANTIBODIES AND THE GONADOTROPHINS PROFILE (LH/FSH) IN EUTHYROID POLYCYSTIC OVARIAN SYNDROME WOMEN.

Authors:  M Sharma; A Modi; M Goyal; P Sharma; P Purohit
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Jan-Mar       Impact factor: 1.104

4.  DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway.

Authors:  Daojuan Wang; Wenqing Wang; Qiao Liang; Xuan He; Yanjie Xia; Shanmei Shen; Hongwei Wang; Qian Gao; Yong Wang
Journal:  J Ovarian Res       Date:  2018-01-10       Impact factor: 4.234

5.  Laparoscopic Ovarian Drilling Reduces Testosterone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio and Improves Clinical Outcome in Women with Polycystic Ovary Syndrome.

Authors:  Priyanka Sinha; Thyagaraju Chitra; Dasari Papa; Hanumanthappa Nandeesha
Journal:  J Hum Reprod Sci       Date:  2019 Jul-Sep

6.  Evaluation of clinical manifestations, health risks, and quality of life among women with polycystic ovary syndrome.

Authors:  Syeda Sidra; Muhammad Haseeb Tariq; Muhammad Junaid Farrukh; Muhammad Mohsin
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

Review 7.  Targeting Metabolic Consequences of Insulin Resistance in Polycystic Ovary Syndrome by D-chiro-inositol and Emerging Nutraceuticals: A Focused Review.

Authors:  Sergio Davinelli; Daria Nicolosi; Cinzia Di Cesare; Giovanni Scapagnini; Roberto Di Marco
Journal:  J Clin Med       Date:  2020-04-02       Impact factor: 4.241

8.  A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome.

Authors:  Lihong Liu; Bo Du; Haiying Zhang; Xiaofei Guo; Zheng Zhou; Aihui Xiu; Chang Liu; Shiyu Su; Hao Ai
Journal:  Chin Med       Date:  2018-08-29       Impact factor: 5.455

9.  Expression of FKBP52 in the ovaries of PCOS rats.

Authors:  Shiyan Song; Yong Tan
Journal:  Int J Mol Med       Date:  2018-11-26       Impact factor: 4.101

Review 10.  Polycystic Ovary Syndrome: A Brain Disorder Characterized by Eating Problems Originating during Puberty and Adolescence.

Authors:  Régine P M Steegers-Theunissen; Rosalieke E Wiegel; Pauline W Jansen; Joop S E Laven; Kevin D Sinclair
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.